Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 12/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338786 | 0.84 | KDM4E (0.47) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL338897 | 0.81 | KDM4E (0.44) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL25378957 | 0.74 | KDM4E (0.53) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL17472767 | 0.73 | ALDH1A1 (0.54) | KDM4ETDP1CNR1 | |
| SCHEMBL4486546 | 0.73 | CYP11B2 (0.40) | KDM4ETDP1CLK4 | |
| SCHEMBL1163252 | 0.72 | ESR2 (0.50) | KDM4E | |
| SCHEMBL338681 | 0.71 | KDM4E (0.44) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL1911495 | 0.71 | HSP90AA1 (0.37) | KDM4EMAPT | |
| SCHEMBL1913162 | 0.71 | CRHR1 (0.42) | KDM4EMAPTTDP1 | |
| SCHEMBL339660 | 0.71 | GSK3A (0.50) | KDM4EMAPTTDP1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | KDM4E 3759/4885MAPT 2167/4885TDP1 3650/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | KDM4E 3759/4885MAPT 2167/4885TDP1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.